Related Experiment Video
Updated: Jun 13, 2025
Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
Published on: July 5, 2017
Procyanidins as potential anticancer agents: mechanisms of action, bioavailability challenges and therapeutic
Adedayo O Ademiluyi1, Olubukola H Oyeniran2, María Luisa Del Prado-Audelo3
1Functional Foods and Nutraceuticals Unit, Department of Biochemistry, Federal University of Technology, Akure, 340252, Nigeria.
Abstract:
Procyanidins (PCs), dietary polyphenols found in fruits, vegetables, and beverages, exhibit potent anticancer properties. Their mechanisms of action involve modulating oxidative stress, inhibiting angiogenesis, inducing apoptosis, and preventing tumor progression. Despite promising preclinical and clinical findings, their therapeutic potential remains underexplored. This review aims to provide a comprehensive analysis of the anticancer properties of PCs, including their bioavailability, pharmacokinetics, and safety. A systematic literature search was conducted across databases such as PubMed, Scopus, and Web of Science, utilizing Medical Subject Headings (MeSH) terms and specific keywords. Studies were selected based on predefined inclusion criteria, focusing on in vitro, in vivo, and clinical evidence. PCs demonstrate anticancer effects through multiple pathways, including inhibition of pro-inflammatory cytokines, suppression of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways, and regulation of apoptosis-related proteins such as BCL2-associated X protein (BAX), B-cell lymphoma 2 (BCL-2), and caspases. PCs demonstrate anticancer effects through multiple pathways, including inhibition of pro-inflammatory cytokines, suppression of the PI3K/AKT/mTOR and MAPK/ERK pathways, and regulation of apoptosis-related proteins such as BAX, BCL-2, and caspases. However, their low oral bioavailability and metabolic instability pose challenges for clinical application. Current research highlights the need for novel delivery systems, such as nanoparticles and liposomes, to enhance systemic absorption and therapeutic efficacy. Ongoing clinical trials are investigating the potential of PCs as adjuvants in cancer therapy, either alone or in combination with chemotherapeutic agents. Future studies should focus on optimizing their pharmacokinetics, exploring synergistic effects with existing treatments, and conducting large-scale clinical trials to validate their efficacy and safety. PCs hold promise as natural anticancer agents, with the potential to complement conventional therapies and improve patient outcomes.
Insights
Procyanidins (PCs), natural polyphenols, show significant anticancer potential by targeting key cellular pathways and inducing apoptosis. Enhancing their bioavailability is crucial for effective clinical application in cancer therapy.
Area of Science:
- Dietary polyphenols research
- Oncology
- Pharmacology
Background:
- Procyanidins (PCs) are dietary polyphenols found in various plant-based foods and beverages.
- PCs exhibit potent anticancer properties through diverse mechanisms, including modulating oxidative stress, inhibiting angiogenesis, and inducing apoptosis.
- Despite promising preclinical and clinical findings, their therapeutic potential is underexplored due to challenges in bioavailability and pharmacokinetics.
Purpose of the Study:
- To provide a comprehensive analysis of the anticancer properties of PCs.
- To review their bioavailability, pharmacokinetics, and safety.
- To identify challenges and future directions for clinical application.
Main Methods:
- Systematic literature search across PubMed, Scopus, and Web of Science.
- Inclusion of studies based on in vitro, in vivo, and clinical evidence.
- Analysis of PC mechanisms including pathway modulation and apoptosis regulation.
Main Results:
- PCs demonstrate anticancer effects by inhibiting pro-inflammatory cytokines and suppressing key signaling pathways like PI3K/AKT/mTOR and MAPK/ERK.
- PCs regulate apoptosis-related proteins such as BAX, BCL-2, and caspases.
- Low oral bioavailability and metabolic instability are identified as major challenges for clinical use.
Conclusions:
- Novel delivery systems like nanoparticles and liposomes are needed to enhance PC absorption and efficacy.
- Further research should focus on optimizing PC pharmacokinetics and exploring synergistic effects with conventional cancer therapies.
- PCs show promise as natural anticancer agents, potentially complementing existing treatments and improving patient outcomes.
Related Concept Videos
02:59Cancer Prevention
Some...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:13Bioavailability: Overview